Professor Espina provides an overview of how individualized cancer treatment is determined
Every individual’s disease is different. Personalized medicine strives to provide the right medicine for the right patient with the lowest toxicity. Personalized cancer therapy using proteomics involves molecular profiling of the patient’s cancer cells to map the susceptible drug targets and thereby guide therapy. Research, like that being done by the Center for Applied Proteomics and Molecular Medicine, provides strategies for personalized treatment with the goal of providing physicians key missing molecular information about the disease in each of their patients and improving the quality of life for patients.
The 5th annual Reverse Phase Protein Array (RPPA) Global Workshop was hosted at George Mason University, Manassas, Virginia on October 12-13, 2015. The methodology and applications for the RPPA technology is constantly evolving. Therefore, pioneers of the technology, experienced users and researchers interested in incorporating the RPPA technology into their portfolio gathered at the RPPA Global Workshop to discuss the technology’s applications for making advancements in personalized medicine; identifying therapeutic targets; discovering and validating biomarkers; and answering other biological questions. They continued to build on the knowledge exchanged at the previous meetings in Houston (USA) 2011, Edinburgh (UK) 2012, Kobe (Japan) 2013, and Paris (France) 2014. Furthermore, academic and industry representatives guided future directions by exploring 1) hot areas in translational science, 2) combination of RPPA with other technologies to answer questions in new fields, 3) FDA policy encompassing development of laboratory tests and the desire to combine diagnostic markers with therapeutics, and 4) funding opportunities to support studies utilizing RPPA. Free exchange of knowledge was shared in workshops, presentations, and technology showcases. The 2016 RPPA Workshop is being held in Germany on September 25-27.
The Side-Out Metastatic Breast cancer trial was announced at the annual meeting of the American Society of Clinical Oncology (ASCO) and is expected to expand into phase two this month.
The pilot study was the first of its kind to utilize novel protein activation mapping technology along with the genomic fingerprint of cancer as a way to find the most effective treatment. Results indicate that while prior standard chemotherapy failed the 25 women who participated in the 2.5 year pilot study, nearly half of the patients enrolled in the Side-Out trail had at least a 30 percent increase in progression-free survival.
This molecular approach creates opportunities for new therapies. For example, if a breast tumor shares the same protein pathway activation shared with lung cancer, then the drug developed to hit that target for lung cancer can be used now for breast cancer. The pilot study included only FDA-approved drugs currently on the market. Additional studies are expected to fold in new drugs as they become available with experimental drug.
Hear what patients and a treating physician has to say: Funded by Volleyball Tournaments, Breast Cancer Pilot Study Succeeds
Based on the results of this trial, CAPMM and the Side-Out Foundation are expanding this study to a new trial that is set to launch within the next month.